Nova Eye Medical Ltd
ASX:EYE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Vaibhav Global Ltd
NSE:VAIBHAVGBL
|
IN |
Nova Eye Medical Ltd
Other Liabilities
Nova Eye Medical Ltd
Other Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Nova Eye Medical Ltd
ASX:EYE
|
Other Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Somnomed Ltd
ASX:SOM
|
Other Liabilities
AU$896k
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
2%
|
|
|
Cochlear Ltd
ASX:COH
|
Other Liabilities
AU$80m
|
CAGR 3-Years
17%
|
CAGR 5-Years
12%
|
CAGR 10-Years
2%
|
|
|
Optiscan Imaging Ltd
ASX:OIL
|
Other Liabilities
AU$30.7k
|
CAGR 3-Years
14%
|
CAGR 5-Years
28%
|
CAGR 10-Years
4%
|
|
|
Austco Healthcare Ltd
ASX:AHC
|
Other Liabilities
AU$42k
|
CAGR 3-Years
0%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
EMvision Medical Devices Ltd
ASX:EMV
|
Other Liabilities
AU$158k
|
CAGR 3-Years
52%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Nova Eye Medical Ltd
Glance View
Nova Eye Medical Ltd. engages in developing suite of novel ophthalmic treatment technologies. The company is headquartered in Adelaide, South Australia and currently employs 130 full-time employees. The firm is focused on developing, manufacturing and selling a portfolio of ophthalmic treatment technologies and devices. Its technologies include iTrack minimally invasive glaucoma surgery (MIGS), which is a consumable surgical device that restores the eye's natural outflow pathway to lower pressure inside the eye and to eliminate patients' reliance on anti-glaucoma medications for mild-moderate glaucoma. Its Molteno3 glaucoma drainage device platform is designed to manage surgical utility and optimize clinical outcomes for long-term intraocular pressure (IOP) control in cases of severe glaucoma. The firm's 2RT is an ophthalmic laser developed for the therapy of patients in the early to intermediate stages of age-related macular degeneration (AMD).
